Humanigen Inc (HGENQ)

[jdc1]

Can someone with a science background give some insight here. Was looking at the Crispr results from their Phase I Car-T trial and I saw the following quote:

"One patient received Dose Level 4 of CTX110. On Day 5, the patient experienced Grade 2 CRS which resolved in 5 days. The PET/CT assessment at Day 25 showed the patient had achieved a complete response. The following day, the patient was hospitalized with febrile neutropenia and developed symptoms of short-term memory loss and confusion. The symptoms eventually progressed to significant obtundation that required intubation. He was initially treated for ICANS with steroids, anakinra and intrathecal chemotherapy without improvement. The patient was later found to have reactivation of HHV-6 and HHV-6 encephalitis and treated with antiviral therapy. The decision was made to withdraw supportive care and the patient died 52 days after CTX110 infusion."

Is this a situation where an antibody like Lenz could have helped the outcome? If so I know management said the collaboration with Kite is not exclusive and they can potentially partner with other companies on the same indication